Google
Click here to Top Secret Fat Loss Secret

Archive for the ‘Urology / Nephrology’ Category

Renal Stone Disease: Treatment For The 21st Century

Sunday, August 10th, 2008

UroToday.com - Renal calculus disease is one of the most ancient afflictions of mankind and remains a common cause for both office and emergency room urologist's visits. Approximately one of eight Caucasian patients forms a urinary tract stone within their lifetime. The recurrence rate for these patients is about 50% ...

Salvage Options For Biochemical Recurrence After Primary Therapy For Prostate Cancer

Sunday, August 10th, 2008

UroToday.com - Despite excellent success rates with radical prostatectomy and radiotherapy for the treatment of prostate cancer, a significant number of patients will experience a rise in their serum prostate specific antigen (PSA) level. A variety of salvage options in this scenario have been investigated and the choice to pursue ...

Surgical Approaches To The Repair Of Urinary Rectal Fistula

Sunday, August 10th, 2008

UroToday.com - In most cases, urinary rectal fistulas will involve bladder to rectum, prostatic urethra to rectum, or in some cases membranous urethra to rectum. Fistulas can be congenital or acquired; the acquired fistulas will be covered in this lecture. As such, treatment must be very individually administered. What must ...

Management Of The Small Renal Mass

Sunday, August 10th, 2008

Small renal masses are defined as stage T1a lesions (less than 4cm), but certainly lesions less than 2cm fall into this definition. There is a 126% increase in the detection of renal cell cancers since 1950, due to increased imaging and incidental detection of renal masses. It is suggested that ...

Interstitial Cystitis And Pelvic Pain Syndromes

Friday, August 8th, 2008

UroToday.com - Objectives: * Discuss the new terminology and disease classification of interstitial cystitis (IC) * Present data on epidemiology of the disease including its overlap with other pelvic organ syndromes * Review current approaches to diagnosis ...

Late Onset Hypogonadism, ADAM, Andropause: What Is It And What Is The Treatment?

Friday, August 8th, 2008

UroToday.com - Late-onset hypogonadism (LOH), or androgen decline in the aging male, is a syndrome caused by the well-known decline in gonadal production of androgens in males that occurs with aging. It is characterized by clinical symptoms that accompany low serum androgen levels. LOH affects a wide range of organ ...

New Data On Nymox BPH Drug To Be Presented At American Urological Association Meeting In Monterey October 26-30

Saturday, August 2nd, 2008

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that new clinical trial data concerning the safety and efficacy of the Company's NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the Annual Meeting of the Western Section of the American Urological Association Meeting being held in Monterey, CA from October ...

Prostate Cancer Detection Rate In Patients With Repeated Extended 21-Sample Needle Biopsy

Thursday, July 31st, 2008

UroToday.com - In an article by a group of French investigators that appears in the online version of European Urology, they examine the issue of whether one negative extended prostate cancer (CaP) biopsy should reassure patients that they do not have CaP. Between 2001 and 2007, 953 men had ...

Performance Of Prostate Specific Antigen For Predicting Prostate Cancer Is Maintained After A Prior Negative Prostate Biopsy

Thursday, July 31st, 2008

UroToday.com - In the August 2008 issue of the Journal of Urology, Dr. Ian Thompson and colleagues explored the performance characteristics of PSA after a previous negative prostate biopsy. The population of men had all undergone prostate biopsy regardless of PSA or digital rectal examination (DRE) findings, thus minimizing ...

Aggressive Approach To Staghorn Calculi-Safety And Efficacy Of Multiple Tracts Percutaneous Nephrolithotomy

Thursday, July 31st, 2008

UroToday.com - Studying a group of 149 patients, twenty-five percent of whom presented with complete staghorn stones, twenty-five percent with borderline stone bulk, and fifty percent with partial staghorn stones, the authors placed an average of 2.6 nephrostomy tubes (2-6 per patient), with a supracostal puncture in nearly 60%.Of note, ...

Perioperative Complications And Early Follow-up With 100 TVT-SECUR Procedures

Thursday, July 31st, 2008

UroToday.com - The TVT procedure has become very popular ever since it was first described by Ulmsten in 1996. Common complications in previously performed surgeries for the treatment of stress urinary incontinence, such as intra-operative blood loss, pelvic and abdominal organ injury, post-operative de novo detrusor instability, dyspareunia and urethral ...

Oestrogen And Benign Prostatic Hyperplasia: Effects On Stromal Cell Proliferation And Local Formation From Androgen

Thursday, July 31st, 2008

UroToday.com - Previous animal studies suggested a role for estrogens in the pathogenesis of benign prostatic hyperplasia (BPH) 1,2. Estrogens interact with two forms of estrogen receptor (ER), ERα and ERβ. We recently reported the differential expression of the two ER subtypes in stromal and epithelial cells derived from human ...

Shock Wave Lithotripsy For Renal Stones Is Not Associated With Hypertension And Diabetes Mellitus

Thursday, July 31st, 2008

UroToday.com - In 2007, a worrisome paper regarding the long-term effects of HM-3 shock wave lithotripsy was published by the Mayo Clinic. In that study of 578 treated patients (288 responded to the questionnaire), with 19 year follow-up matched to a control population with untreated urinary stones, a statistically significant ...

Sunitinib Malate Is Active Against Human Urothelial Carcinoma And Enhances The Activity Of Cisplatin In A Preclinical Model

Thursday, July 31st, 2008

UroToday.com - Standard front-line cisplatin-based combination chemotherapy for metastatic transitional cell carcinoma (TCC) with either MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) or GC (gemcitabine, cisplatin) yields a median survival of approximately 15 months. The response rate with these regimens is 40-60% and subsequent progression is almost universal, with salvage chemotherapy being ...

What Is A Year Of Human Life Worth? Updating The Renal Dialysis Cost-Effectiveness Standard

Thursday, July 31st, 2008

A quality-adjusted year of human life is worth $129,090, according to a study to appear in Value in Health. Chris Lee of The Wharton School of the University of Pennsylvania and Glenn Chertow and Stefanos Zenios of Stanford University sought to find the worth of a year of human ...